Posted by Michael Wonder on 26 Feb 2024
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome (draft guidance)
22 February 2024 - NICE has published further draft guidance on the use of setmelanotide acetate.
Setmelanotide acetate is recommended as an option for the treatment of patients aged 6 years and over with obesity and hyperphagia in genetically confirmed Bardet-Biedl syndrome only if they are aged between 6 and 17 when treatment starts.
